As I grasp at straws trying to figure out why such a good drug prospect like Mipsagargin could go to waste with over 150 million spent as good results , I have to think that there in a renewed interest in the drug . Maybe the company involved in the patent buys them out or at least pays decent royalties. Yes , must be in the June report for the quarter as has to be somewhere .
News 
Market Data 
Discover 
